• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Trubion Pharmaceuticals, Inc. (TRBN) - Financial and Strategic Analysis Review Product Image

Trubion Pharmaceuticals, Inc. (TRBN) - Financial and Strategic Analysis Review

  • ID: 1367947
  • September 2010
  • 32 pages
  • GlobalData

Trubion Pharmaceuticals Inc. (Trubion), formerly Genecraft, LLC is a bio-pharmaceutical company engaged in the development of protein therapeutic product candidates for the treatment of autoimmune diseases and cancer. It works with a mission to develop a variety of first-in-class and best-in-class products, customized for optimal safety, efficacy, and convenience in order to provide improved patient benefits. The company's product candidates are small modular immuno pharmaceuticals (SMIP) that are designed using its custom drug assembly technology. TRU-015 is the lead product of Trubion, which is in phase IIb clinical trial for the treatment of rheumatoid arthritis.

Trubion Pharmaceuticals, Inc. Key Recent Developments

Aug 16, 2010 Trubion Reports Net Loss Of $5.7 Million For Q2 2010
Jun 03, 2010 Trubion Wins Genentech And Biogen Idec Patent Appeal
May 06, 2010 Trubion Reports Net Loss Of $6.1 Million For Q1 2010
Jan 11, 2010 Trubion, Pfizer Initiate Phase 2 Rheumatoid Arthritis Study
Dec 08, 2009 Trubion, Facet Biotech Present Positive TRU-016 Data

This comprehensive SWOT profile of Trubion Pharmaceuticals, Inc. provides you an in-depth strategic READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Section 1 - About the Company
Trubion Pharmaceuticals, Inc. - Key Facts
Trubion Pharmaceuticals, Inc. - Key Employees
Trubion Pharmaceuticals, Inc. - Key Employee Biographies
Trubion Pharmaceuticals, Inc. - Major Products and Services
Trubion Pharmaceuticals, Inc. - History
Trubion Pharmaceuticals, Inc. - Company Statement
Trubion Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Section 2 - Company Analysis
Trubion Pharmaceuticals, Inc. - Business Description
Trubion Pharmaceuticals, Inc. - SWOT Analysis
SWOT Analysis - Overview
Trubion Pharmaceuticals, Inc. - Strengths
Strength - Proprietary Product Technologies
Strength - Strong Product Portfolio
Strength - Expanding Market Share
Strength - Strong Liquidity Position
Trubion Pharmaceuticals, Inc. - Weaknesses
Weakness - Negative Margins
Weakness - Low Return on Equity
Trubion Pharmaceuticals, Inc. - Opportunities
Opportunity - Strategic Collaborations
Opportunity - Emerging Markets
Opportunity - Growing Oncology Market
Trubion Pharmaceuticals, Inc. - Threats
Threat - Tightening of FDA’s Regulatory Oversight
Threat - Intense Competition
Threat - Uncertain R&D Outcomes
Trubion Pharmaceuticals, Inc. - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Recent Developments
Aug 16, 2010: Trubion Reports Net Loss Of $5.7 Million For Q2 2010
Jun 03, 2010: Trubion Wins Genentech And Biogen Idec Patent Appeal
May 06, 2010: Trubion Reports Net Loss Of $6.1 Million For Q1 2010
Jan 11, 2010: Trubion, Pfizer Initiate Phase 2 Rheumatoid Arthritis Study
Dec 08, 2009: Trubion, Facet Biotech Present Positive TRU-016 Data
Nov 16, 2009: Trubion Names Steven Gillis As Acting President
Aug 28, 2009: Facet Biotech Signs Worldwide Collaboration Agreement With Trubion
Aug 06, 2009: Trubion Pharmaceuticals Reports $4.1m Q2 Revenue
Jun 22, 2009: Trubion Extends Research Period With Wyeth
Feb 25, 2009: Trubion Reduces Work-Force by 25%
Section 5 - Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

Trubion Pharmaceuticals Inc. (Trubion), formerly Genecraft, LLC is a bio-pharmaceutical company engaged in the development of protein therapeutic product candidates for the treatment of autoimmune diseases and cancer. It works with a mission to develop a variety of first-in-class and best-in-class products, customized for optimal safety, efficacy, and convenience in order to provide improved patient benefits. The company's product candidates are small modular immuno pharmaceuticals (SMIP) that are designed using its custom drug assembly technology. TRU-015 is the lead product of Trubion, which is in phase IIb clinical trial for the treatment of rheumatoid arthritis.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS